RxDoctor Payments Data

Christopher Winslow, MD

Psychosomatic Medicine · Mountain Home, ARNPI 1063631661

Payments from drug & device makers

$2,096in general payments, 2019–2025

Across 51 payments — averaging $41.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$926
  • Neuronetics, Inc.$650
  • Axsome Therapeutics, Inc.$137
  • Idorsia Pharmaceuticals US Inc$121
  • Alkermes, Inc.$56
  • E.r. Squibb & Sons, L.L.C.$46
  • plus $159 from 6 others

What the payments were for

  • Travel & lodging$53726%
  • Food & beverage$1,47971%
  • Education$804%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few psychosomatic medicine providers in Arkansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$74,542
Medicare patients
84
Services billed
1,310

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl280$334,397
AustedoDeutetrabenazine13$133,819
Abilify MaintenaAripiprazole21$58,256
ProvigilModafinil11$48,467
LybalviOlanzapine/Samidorphan Malate11$16,421
AuvelityDextromethorphan Hbr/Bupropion12$13,090
BelsomraSuvorexant29$12,540
TrintellixVortioxetine Hydrobromide19$8,885
Quetiapine Fumarate ErQuetiapine Fumarate150$8,124
Fluphenazine Hcl28$6,117
VyvanseLisdexamfetamine Dimesylate15$5,086
Aripiprazole225$4,718
Clonidine47$3,965
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine117$3,905
DayvigoLemborexant12$3,771

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$926$334,397280 claims
Teva Pharmaceuticals USA, Inc.Austedo$36$133,81913 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$28$58,25621 claims
Alkermes, Inc.Lybalvi$56$16,42111 claims
Axsome Therapeutics, Inc.Auvelity$137$13,09012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychosomatic medicine providers in Arkansason file to place this against a meaningful peer group, so we don't.

Where these figures come from

Is this you, or does something look wrong? →